Company: GHRS
Filing Date: 2025-10-14
Form Type: 6-K
Source: 0001140361-25-038026
Chunk: 0

Company: GH Research PLC
Filing Date: 2025-10-14
Form: 6-K
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

| Form 20-F | ☒ |     | Form 40-F |

GH Research PLC announces the presentation of data from its GH001-TRD-201 clinical trial at the 38 thEuropean College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 11-14, 2025, in Amsterdam, the Netherlands (the “Congress”). A copy of the presentation delivered by Prof. Wiesław J. Cubała, MD, PhD, on October 13, 2025, as part of the Novel Therapies Symposium during the Congress, is attached hereto as Exhibit 99.1. 1 EXHIBIT INDEX

| 99.1 | Presentation by Prof. Wiesław J. Cubała with Title: Long-Term Data for GH001 in Patients with Treatment-Resistant Depression |

2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: October 14, 2025 | GH Research PLC |                         |
|:-----------------------|:----------------|:------------------------|
|                        | By:             | /s/ Julie Ryan          |
|                        | Name:           | Julie Ryan              |
|                        | Title:          | Vice President, Finance |

3